...
首页> 外文期刊>Resuscitation. >Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular fibrillation cardiac arrest
【24h】

Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular fibrillation cardiac arrest

机译:预防性利多卡因在院外室性心律失常患者的复苏后护理中的应用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Antiarrhythmic drugs like lidocaine are usually given to promote return of spontaneous circulation (ROSC) during ongoing out-of-hospital cardiac arrest (OHCA) from ventricular fibrillation/tachycardia (VF/VT). Whether administering such drugs prophylactically for post-resuscitation care after ROSC prevents re-arrest and improves outcome is unstudied. Methods: We evaluated a cohort of 1721 patients with witnessed VF/VT OHCA who did (1296) or did not receive prophylactic lidocaine (425) at first ROSC. Study endpoints included re-arrest, hospital admission and survival. Results: Prophylacic lidocaine recipients and non-recipients were comparable, except for shorter time to first ROSC and higher systolic blood pressure at ROSC in those receiving lidocaine. After initial ROSC, arrest from VF/VT recurred in 16.7% and from non-shockable arrhythmias in 3.2% of prophylactic lidocaine recipients, 93.5% of whom were admitted to hospital and 62.4% discharged alive, as compared with 37.4%, 7.8%, 84.9% and 44.5%, of corresponding non-recipients (all p<. 0.0001). Adjusted for pertinent covariates, prophylactic lidocaine was independently associated with reduced odds of re-arrest from VF/VT, odds ratio, (95% confidence interval) 0.34 (0.26-0.44) and from nonshockable arrhythmias (0.47 (0.29-0.78)); a higher hospital admission rate (1.88, (1.28-2.76)) and improved survival to discharge (1.49 (1.15-1.95)). However in a propensity score-matched sensitivity analysis, lidocaine's only beneficial association with outcome was in a lower incidence of recurrent VF/VT arrest. Conclusions: Administration of prophylactic lidocaine upon ROSC after OHCA was consistently associated with less recurrent VF/VT arrest, and therapeutic equipoise for other measures. The prospect of a promising association between lidocaine prophylaxis and outcome, without evidence of harm, warrants further investigation.
机译:背景:抗心律失常药物(如利多卡因)通常用于在持续的室颤/心动过速(VF / VT)导致院外心脏骤停(OHCA)期间促进自发循环(ROSC)的恢复。在ROSC后是否为预防性使用此类药物进行复苏后的护理尚不能研究,以防止再次发作并改善预后。方法:我们评估了1721例在首次ROSC时确诊为VF / VT OHCA的患者(1296例)或未接受预防性利多卡因(425例)的队列研究。研究终点包括再次逮捕,入院和生存。结果:接受利多卡因的接受者和未接受者的利多卡因具有可比性,只是接受利多卡因者的首次ROSC时间较短且ROSC的收缩压较高。最初的ROSC后,预防性利多卡因接受者中VF / VT的逮捕发生率分别为16.7%和非电击性心律失常,其中93.5%入院和62.4%活着出院,而37.4%,7.8%,分别有84.9%和44.5%的相应非收件人(所有p <.0.0001)。校正相关协变量后,预防性利多卡因与VF / VT,比值比(95%置信区间)0.34(0.26-0.44)和不可电击性心律不齐(0.47(0.29-0.78))降低的可能性相关。更高的住院率(1.88,(1.28-2.76))和出院生存率提高(1.49(1.15-1.95))。然而,在倾向评分匹配的敏感性分析中,利多卡因与预后的唯一有益关联是复发性VF / VT停搏的发生率较低。结论:OHCA后在ROSC上给予预防性利多卡因与减少复发性VF / VT停搏以及其他措施的治疗平衡有关。利多卡因预防和预后之间有希望的联系的前景,没有伤害证据,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号